Liminal BioSciences: Up on FDA approval for U.S. plasma collection center

Liminal BioSciences

12/01/2021 15:13

** U.S.-listed shares of Canadian drugmaker  LMNL.O  rise
8.9% to $5
    ** Co receives FDA approval for its U.S.-based plasma
collection center  urn:newsml:reuters.com:*:nCNW6G0Nfa
    ** Approval granted to its U.S. unit, Prometic
Biotherapeutics Inc
    ** The center, which started operations in early 2020, is
now licensed to collect and introduce into interstate commerce
human source plasma for further manufacturing in U.S.
    ** LMNL's lead plasma-derived candidate, Ryplazim, for
treatment of genetic disorder that leads to lesions on mucous
membranes is currently under FDA review with health agency
expected to deliver decision by June 5
    ** Including session's gain, stock up ~19% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))